FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 339:953-959 October 1, 1998 Number 14 Next

	Full Text PDF Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited PubMed Citation

ABSTRACT

Background There is increasing evidence of genetic factors leading to obesity, but the exact genes involved have not been defined. Peroxisome-proliferator–activated receptor 2 (PPAR2) is a transcription factor that has a key role in adipocyte differentiation, and therefore mutations of the gene for this factor might predispose people to obesity.

Methods We studied 358 unrelated German subjects, including 121 obese subjects (defined as those with a body-mass index [the weight in kilograms divided by the square of the height in meters] of more than 29). We evaluated these subjects for mutations in the gene for PPAR2 at or near a site of serine phosphorylation at position 114 that negatively regulates the transcriptional activity of the protein, using a polymerase-chain-reaction–based assay coupled with specific endonuclease digestion. The activity of the mutation identified was analyzed by retroviral transfection and overexpression in murine fibroblasts.

Results Four of the 121 obese subjects had a missense mutation in the gene for PPAR2 that resulted in the conversion of proline to glutamine at position 115, as compared with none of the 237 subjects of normal weight (P=0.01). All the subjects with the mutant allele were markedly obese, with body-mass-index values ranging from 37.9 to 47.3, as compared with a mean of 33.6 in the other obese subjects. Overexpression of the mutant gene in murine fibroblasts led to the production of a protein in which the phosphorylation of serine at position 114 was defective, as well as to accelerated differentiation of the cells into adipocytes and greater cellular accumulation of triglyceride than with the wild-type PPAR2. These effects were similar to those of an in vitro mutation created directly at the Ser114 phosphorylation site.

Conclusions A Pro115Gln mutation in PPAR2 accelerates the differentiation of adipocytes and may cause obesity.

Source Information

From the Joslin Diabetes Center and Harvard Medical School, Boston (M.R., C.R.K.); the Klinik II und Poliklinik für Innere Medizin, Universität zu Köln, Cologne, Germany (M.R., D.M.-W., W.K.); and the Medizinische Klinik und Poliklinik, Bergmannsheil, Ruhr-Universität Bochum, Bochum, Germany (A.P.).

Address reprint requests to Dr. Kahn at the Joslin Diabetes Center, Research Division, Section on Cellular and Molecular Physiology, 1 Joslin Pl., Boston, MA 02215.

Full Text of this Article

This article has been cited by other articles:

• Lehmann, D. F., Lohray, B. B. (2008). A Lesson in Moderation: Applying Pharmacodynamics to Clarify the Relationship Between Thiazolidinediones and Adverse Vascular Outcomes in Type 2 Diabetes. J Clin Pharmacol 48: 999-1002 [Full Text]  
• Ruan, X., Zheng, F., Guan, Y. (2008). PPARs and the kidney in metabolic syndrome. Am. J. Physiol. Renal Physiol. 294: F1032-F1047 [Abstract] [Full Text]  
• Musaad, S., Haynes, E. N. (2007). Biomarkers of Obesity and Subsequent Cardiovascular Events. Epidemiol Rev 0: mxm005v1- [Abstract] [Full Text]  
• Monajemi, H., Zhang, L., Li, G., Jeninga, E. H., Cao, H., Maas, M., Brouwer, C. B., Kalkhoven, E., Stroes, E., Hegele, R. A., Leff, T. (2007). Familial Partial Lipodystrophy Phenotype Resulting from a Single-Base Mutation in Deoxyribonucleic Acid-Binding Domain of Peroxisome Proliferator-Activated Receptor-{gamma}. J. Clin. Endocrinol. Metab. 92: 1606-1612 [Abstract] [Full Text]  
• Gilde, A. J., Fruchart, J.-C., Staels, B. (2006). Peroxisome Proliferator-Activated Receptors at the Crossroads of Obesity, Diabetes, and Cardiovascular Disease. J Am Coll Cardiol 48: A24-A32 [Abstract] [Full Text]  
• Porter, J R, Barrett, T G (2005). Monogenic syndromes of abnormal glucose homeostasis: clinical review and relevance to the understanding of the pathology of insulin resistance and {beta} cell failure. J. Med. Genet. 42: 893-902 [Abstract] [Full Text]  
• Meirhaeghe, A., Cottel, D., Amouyel, P., Dallongeville, J. (2005). Association Between Peroxisome Proliferator-Activated Receptor {gamma} Haplotypes and the Metabolic Syndrome in French Men and Women. Diabetes 54: 3043-3048 [Abstract] [Full Text]  
• Sharma, A., Chavali, S., Mahajan, A., Tabassum, R., Banerjee, V., Tandon, N., Bharadwaj, D. (2005). Genetic Association, Post-translational Modification, and Protein-Protein Interactions in Type 2 Diabetes Mellitus. Mol. Cell. Proteomics 4: 1029-1037 [Abstract] [Full Text]  
• Pischon, T., Pai, J. K., Manson, J. E., Hu, F. B., Rexrode, K. M., Hunter, D., Rimm, E. B. (2005). Peroxisome Proliferator-Activated Receptor-{gamma}2 P12A Polymorphism and Risk of Coronary Heart Disease in US Men and Women. Arterioscler. Thromb. Vasc. Bio. 25: 1654-1658 [Abstract] [Full Text]  
• Paracchini, V., Pedotti, P., Taioli, E. (2005). Genetics of Leptin and Obesity: A HuGE Review. Am J Epidemiol 162: 101-114 [Abstract] [Full Text]  
• Hansen, S. K., Nielsen, E.-M. D., Ek, J., Andersen, G., Glumer, C., Carstensen, B., Mouritzen, P., Drivsholm, T., Borch-Johnsen, K., Jorgensen, T., Hansen, T., Pedersen, O. (2005). Analysis of Separate and Combined Effects of Common Variation in KCNJ11 and PPARG on Risk of Type 2 Diabetes. J. Clin. Endocrinol. Metab. 90: 3629-3637 [Abstract] [Full Text]  
• McGettrick, A. J., Feener, E. P., Kahn, C. R. (2005). Human Insulin Receptor Substrate-1 (IRS-1) Polymorphism G972R Causes IRS-1 to Associate with the Insulin Receptor and Inhibit Receptor Autophosphorylation. J. Biol. Chem. 280: 6441-6446 [Abstract] [Full Text]  
• Knouff, C., Auwerx, J. (2004). Peroxisome Proliferator-Activated Receptor-{gamma} Calls for Activation in Moderation: Lessons from Genetics and Pharmacology. Endocr. Rev. 25: 899-918 [Abstract] [Full Text]  
• Guan, Y. (2004). Peroxisome Proliferator-Activated Receptor Family and Its Relationship to Renal Complications of the Metabolic Syndrome. J. Am. Soc. Nephrol. 15: 2801-2815 [Abstract] [Full Text]  
• Yamashita, D., Yamaguchi, T., Shimizu, M., Nakata, N., Hirose, F., Osumi, T. (2004). The transactivating function of peroxisome proliferator-activated receptor {gamma} is negatively regulated by SUMO conjugation in the amino-terminal domain. GENES CELLS 9: 1017-1029 [Abstract] [Full Text]  
• Parton, L. E., Diraison, F., Neill, S. E., Ghosh, S. K., Rubino, M. A., Bisi, J. E., Briscoe, C. P., Rutter, G. A. (2004). Impact of PPAR{gamma} overexpression and activation on pancreatic islet gene expression profile analyzed with oligonucleotide microarrays. Am. J. Physiol. Endocrinol. Metab. 287: E390-E404 [Abstract] [Full Text]  
• Haluzik, M., Colombo, C., Gavrilova, O., Chua, S., Wolf, N., Chen, M., Stannard, B., Dietz, K. R., Le Roith, D., Reitman, M. L. (2004). Genetic Background (C57BL/6J Versus FVB/N) Strongly Influences the Severity of Diabetes and Insulin Resistance in ob/ob Mice. Endocrinology 145: 3258-3264 [Abstract] [Full Text]  
• Shin, H. D., Park, B. L., Kim, L. H., Jung, H. S., Cho, Y. M., Moon, M. K., Park, Y. J., Lee, H. K., Park, K. S. (2004). Genetic Polymorphisms in Peroxisome Proliferator-Activated Receptor {delta} Associated With Obesity. Diabetes 53: 847-851 [Abstract] [Full Text]  
• Farooqi, I.S., O'Rahilly, S. (2004). Monogenic Human Obesity Syndromes. Recent Prog Horm Res 59: 409-424 [Abstract] [Full Text]  
• Moyes, C. D. (2003). Controlling muscle mitochondrial content. J. Exp. Biol. 206: 4385-4391 [Abstract] [Full Text]  
• Orio, F. Jr., Matarese, G., Di Biase, S., Palomba, S., Labella, D., Sanna, V., Savastano, S., Zullo, F., Colao, A., Lombardi, G. (2003). Exon 6 and 2 Peroxisome Proliferator-Activated Receptor-{gamma} Polymorphisms in Polycystic Ovary Syndrome. J. Clin. Endocrinol. Metab. 88: 5887-5892 [Abstract] [Full Text]  
• Gardner, O. S., Dewar, B. J., Earp, H. S., Samet, J. M., Graves, L. M. (2003). Dependence of Peroxisome Proliferator-activated Receptor Ligand-induced Mitogen-activated Protein Kinase Signaling on Epidermal Growth Factor Receptor Transactivation. J. Biol. Chem. 278: 46261-46269 [Abstract] [Full Text]  
• Masud, S, Ye, S (2003). Effect of the peroxisome proliferator activated receptor-{gamma} gene Pro12Ala variant on body mass index: a meta-analysis. J. Med. Genet. 40: 773-780 [Full Text]  
• Gupta, R. A., Sarraf, P., Mueller, E., Brockman, J. A., Prusakiewicz, J. J., Eng, C., Willson, T. M., DuBois, R. N. (2003). Peroxisome Proliferator-activated Receptor {gamma}-mediated Differentiation: A MUTATION IN COLON CANCER CELLS REVEALS DIVERGENT AND CELL TYPE-SPECIFIC MECHANISMS. J. Biol. Chem. 278: 22669-22677 [Abstract] [Full Text]  
• Gurnell, M., Savage, D. B., Chatterjee, V. K. K., O'Rahilly, S. (2003). The Metabolic Syndrome: Peroxisome Proliferator-Activated Receptor {gamma} and Its Therapeutic Modulation. J. Clin. Endocrinol. Metab. 88: 2412-2421 [Abstract] [Full Text]  
• Korc, M. (2003). Diabetes Mellitus in the Era of Proteomics. Mol. Cell. Proteomics 2: 399-404 [Full Text]  
• Bluher, M., Lubben, G., Paschke, R. (2003). Analysis of the Relationship Between the Pro12Ala Variant in the PPAR-{gamma}2 Gene and the Response Rate to Therapy With Pioglitazone in Patients With Type 2 Diabetes. Diabetes Care 26: 825-831 [Abstract] [Full Text]  
• Meirhaeghe, A., Fajas, L., Gouilleux, F., Cottel, D., Helbecque, N., Auwerx, J., Amouyel, P. (2003). A Functional Polymorphism in a STAT5B Site of the Human PPAR{gamma}3 Gene Promoter Affects Height and Lipid Metabolism in a French Population. Arterioscler. Thromb. Vasc. Bio. 23: 289-294 [Abstract] [Full Text]  
• Patel, N. G., Holder, J. C., Smith, S. A., Kumar, S., Eggo, M. C. (2003). Differential Regulation of Lipogenesis and Leptin Production by Independent Signaling Pathways and Rosiglitazone During Human Adipocyte Differentiation. Diabetes 52: 43-50 [Abstract] [Full Text]  
• Labib, M (2003). The investigation and management of obesity. J. Clin. Pathol. 56: 17-25 [Abstract] [Full Text]  
• Hegele, R. A., Cao, H., Frankowski, C., Mathews, S. T., Leff, T. (2002). PPARG F388L, a Transactivation-Deficient Mutant, in Familial Partial Lipodystrophy. Diabetes 51: 3586-3590 [Abstract] [Full Text]  
• Rieusset, J., Touri, F., Michalik, L., Escher, P., Desvergne, B., Niesor, E., Wahli, W. (2002). A New Selective Peroxisome Proliferator-Activated Receptor {gamma} Antagonist with Antiobesity and Antidiabetic Activity. Mol. Endocrinol. 16: 2628-2644 [Abstract] [Full Text]  
• Sewter, C., Blows, F., Considine, R., Vidal-Puig, A., O'Rahilly, S. (2002). Differential Effects of Adiposity on Peroxisomal Proliferator-Activated Receptor {gamma}1 and {gamma}2 Messenger Ribonucleic Acid Expression in Human Adipocytes. J. Clin. Endocrinol. Metab. 87: 4203-4207 [Abstract] [Full Text]  
• Stumvoll, M., Haring, H. (2002). The Peroxisome Proliferator-Activated Receptor-{gamma}2 Pro12Ala Polymorphism. Diabetes 51: 2341-2347 [Abstract] [Full Text]  
• Tamori, Y., Masugi, J., Nishino, N., Kasuga, M. (2002). Role of Peroxisome Proliferator-Activated Receptor-{gamma} in Maintenance of the Characteristics of Mature 3T3-L1 Adipocytes. Diabetes 51: 2045-2055 [Abstract] [Full Text]  
• Schneider, J., Kreuzer, J., Hamann, A., Nawroth, P. P., Dugi, K. A. (2002). The Proline 12 Alanine Substitution in the Peroxisome Proliferator-Activated Receptor-{gamma}2 Gene Is Associated With Lower Lipoprotein Lipase Activity in Vivo. Diabetes 51: 867-870 [Abstract] [Full Text]  
• Walczak, R., Tontonoz, P. (2002). PPARadigms and PPARadoxes: expanding roles for PPAR{gamma} in the control of lipid metabolism. J. Lipid Res. 43: 177-186 [Abstract] [Full Text]  
• Pihlajamaki, J., Austin, M., Edwards, K., Laakso, M. (2001). A Major Gene Effect on Fasting Insulin and Insulin Sensitivity in Familial Combined Hyperlipidemia. Diabetes 50: 2396-2401 [Abstract] [Full Text]  
• Ko, C., Lee, T.-L., Lau, P. W., Li, J., Davis, B. T., Voyiaziakis, E., Allison, D. B., Chua, S. C. , Jr., Huang, L.-S. (2001). Two novel quantitative trait loci on mouse chromosomes 6 and 4 independently and synergistically regulate plasma apoB levels. J. Lipid Res. 42: 844-855 [Abstract] [Full Text]  
• Douglas, J. A., Erdos, M. R., Watanabe, R. M., Braun, A., Johnston, C. L., Oeth, P., Mohlke, K. L., Valle, T. T., Ehnholm, C., Buchanan, T. A., Bergman, R. N., Collins, F. S., Boehnke, M., Tuomilehto, J. (2001). The Peroxisome Poliferator-Activated Receptor-{gamma}2 Pro12Ala Variant: Association With Type 2 Diabetes and Trait Differences. Diabetes 50: 886-890 [Abstract] [Full Text]  
• Hsueh, W.-C., Mitchell, B. D., Schneider, J. L., St. Jean, P. L., Pollin, T. I., Ehm, M. G., Wagner, M. J., Burns, D. K., Sakul, H., Bell, C. J., Shuldiner, A. R. (2001). Genome-Wide Scan of Obesity in the Old Order Amish. J. Clin. Endocrinol. Metab. 86: 1199-1205 [Abstract] [Full Text]  
• Luan, J.'a., Browne, P. O., Harding, A.-H., Halsall, D. J., O’Rahilly, S., Chatterjee, V.K. K., Wareham, N. J. (2001). Evidence for Gene-Nutrient Interaction at the PPAR{gamma} Locus. Diabetes 50: 686-689 [Abstract] [Full Text]  
• Hasstedt, S. J., Ren, Q.-F., Teng, K., Elbein, S. C. (2001). Effect of the Peroxisome Proliferator-Activated Receptor-{{gamma}}2 Pro12Ala Variant on Obesity, Glucose Homeostasis, and Blood Pressure in Members of Familial Type 2 Diabetic Kindreds. J. Clin. Endocrinol. Metab. 86: 536-541 [Abstract] [Full Text]  
• Hsueh, W. A., Jackson, S., Law, R. E. (2001). Control of Vascular Cell Proliferation and Migration by PPAR-{gamma}: A new approach to the macrovascular complications of diabetes. Diabetes Care 24: 392-397 [Abstract] [Full Text]  
• Fasshauer, M., Klein, J., Kriauciunas, K. M., Ueki, K., Benito, M., Kahn, C. R. (2001). Essential Role of Insulin Receptor Substrate 1 in Differentiation of Brown Adipocytes. Mol. Cell. Biol. 21: 319-329 [Abstract] [Full Text]  
• Arioglu, E., Duncan-Morin, J., Sebring, N., Rother, K. I., Gottlieb, N., Lieberman, J., Herion, D., Kleiner, D. E., Reynolds, J., Premkumar, A., Sumner, A. E., Hoofnagle, J., Reitman, M. L., Taylor, S. I. (2000). Efficacy and Safety of Troglitazone in the Treatment of Lipodystrophy Syndromes. ANN INTERN MED 133: 263-274 [Abstract] [Full Text]  
• Devlin, M. J., Yanovski, S. Z., Wilson, G. T. (2000). Obesity: What Mental Health Professionals Need to Know. Am. J. Psychiatry 157: 854-866 [Abstract] [Full Text]  
• Fredriks, A M, van Buuren, S, Wit, J M, Verloove-Vanhorick, S P (2000). Body index measurements in 1996-7 compared with 1980. Arch. Dis. Child. 82: 107-112 [Abstract] [Full Text]  
• Knoblauch, H., Busjahn, A., Muller-Myhsok, B., Faulhaber, H.-D., Schuster, H., Uhlmann, R., Luft, F. C. (1999). Peroxisome Proliferator-Activated Receptor {gamma} Gene Locus Is Related to Body Mass Index and Lipid Values in Healthy Nonobese Subjects. Arterioscler. Thromb. Vasc. Bio. 19: 2940-2944 [Abstract] [Full Text]  
• Wang, X. L., Oosterhof, J., Duarte, N. (1999). Peroxisome proliferator-activated receptor {gamma} C161->T polymorphism and coronary artery disease. Cardiovasc Res 44: 588-594 [Abstract] [Full Text]  
• Yanovski, J. A., Yanovski, S. Z. (1999). Recent Advances in Basic Obesity Research. JAMA 282: 1504-1506 [Full Text]  
• Desvergne, B., Wahli, W. (1999). Peroxisome Proliferator-Activated Receptors: Nuclear Control of Metabolism. Endocr. Rev. 20: 649-688 [Abstract] [Full Text]  
• Chen, D., Garg, A. (1999). Monogenic disorders of obesity and body fat distribution. J. Lipid Res. 40: 1735-1746 [Abstract] [Full Text]  
• Valve, R., Sivenius, K., Miettinen, R., Pihlajamaki, J., Rissanen, A., Deeb, S. S., Auwerx, J., Uusitupa, M., Laakso, M. (1999). Two Polymorphisms in the Peroxisome Proliferator-Activated Receptor-{gamma} Gene Are Associated with Severe Overweight among Obese Women. J. Clin. Endocrinol. Metab. 84: 3708-3712 [Abstract] [Full Text]  
• Poretsky, L., Cataldo, N. A., Rosenwaks, Z., Giudice, L. C. (1999). The Insulin-Related Ovarian Regulatory System in Health and Disease. Endocr. Rev. 20: 535-582 [Abstract] [Full Text]  
• Eubank, D. W., Duplus, E., Williams, S. C., Forest, C., Beale, E. G. (2001). Peroxisome Proliferator-activated Receptor gamma and Chicken Ovalbumin Upstream Promoter Transcription Factor II Negatively Regulate the Phosphoenolpyruvate Carboxykinase Promoter via a Common Element*. J. Biol. Chem. 276: 30561-30569 [Abstract] [Full Text]